| scholarly article | Q13442814 |
| P2093 | author name string | Kenjiro Aogi | |
| Seiki Takashima | |||
| Hiroyoshi Doihara | |||
| Naruto Taira | |||
| Shozo Ohsumi | |||
| Daisuke Takabatake | |||
| Sachiko Kiyoto | |||
| Fumikata Hara | |||
| Shigemitu Takashima | |||
| Tadahiko Sien | |||
| P2860 | cites work | Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials | Q29547513 |
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Docetaxel-related side effects and their management | Q33337573 | ||
| Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics | Q36597641 | ||
| Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials | Q37038642 | ||
| Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer | Q44902909 | ||
| Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. | Q46127853 | ||
| Adjuvant docetaxel for node-positive breast cancer | Q46522790 | ||
| Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials | Q46828225 | ||
| 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. | Q53243856 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chemotherapy | Q974135 |
| docetaxel | Q420436 | ||
| feasibility study | Q755009 | ||
| P304 | page(s) | 478-483 | |
| P577 | publication date | 2009-06-01 | |
| P1433 | published in | Japanese Journal of Clinical Oncology | Q2231629 |
| P1476 | title | Feasibility study of docetaxel with cyclophosphamide as adjuvant chemotherapy for Japanese breast cancer patients. | |
| P478 | volume | 39 |
| Q34343470 | Adjuvant Docetaxel and Cyclophosphamide (DC) with prophylactic granulocyte colony-stimulating factor (G-CSF) on days 8 &12 in breast cancer patients: a retrospective analysis |
| Q53213551 | Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer. |
| Q53175518 | Docetaxel, cyclophosphamide, and trastuzumab as neoadjuvant chemotherapy for HER2-positive primary breast cancer. |
| Q48332647 | Docetaxel/cyclophosphamide chemotherapy in older patients with breast cancer. |
| Q64103689 | Early neutropenia on day 8 treated with adjuvant Docetaxel-based chemotherapy in early breast cancer patients: Putative mechanisms within the neutrophil pool system |
| Q38026783 | Effectiveness of 3-week intervention of Shi Quan Da Bu Tang for alleviating hematotoxicity among patients with breast carcinoma receiving chemotherapy |
| Q37724850 | Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network study |
| Q51017077 | Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in breast cancer patients: a retrospective analysis. |
| Q38682028 | Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis |
| Q27690879 | Optimal management of breast cancer in the elderly patient: current perspectives |
| Q35237134 | Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy |
| Q37976586 | Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis |
| Q36897773 | Real-world impact of granulocyte-colony stimulating factor on febrile neutropenia |
| Q38711952 | Taxane-induced arthralgia and myalgia: A literature review |
| Q35573019 | The cost-utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer |
| Q38580333 | The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis |
| Q38858924 | Toxicity profile differences of adjuvant docetaxel/cyclophosphamide (TC) between Asian and Caucasian breast cancer patients |
Search more.